Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
they didn't have the votes for the 50 billion shares so kenny adjourned it until they find the votes LOL....
they were using dominion voting machines
my question to kenny all past sec filing so very little money spent on RD and most of the money spent on salaries.....I dont see that changing with the increasing the share to 50billion.of course the coward didn't read it
I hoping PMCB is under a penny when meeting starts
just check the link registration will begin in 50 min
FDA rejected PMCBs IND
all shareholders of Bristol should email them and tell you are unhappy with Hidalgo’s relationship with PMCb
guarantee waggy doesn't answer one touch question tomorrow
Crabtree & Hidalgo’s are has beens just in it for the money
PMCB Failures
KW officially takes over as President of NVLX worst thing that ever happen
NVLX immediately acquires 14.5% equity interest in Austrianova. First vision 14.5% of zero is zero
NVLX contracts with Austrianova to encapsulate cells for clinical trials. that never happened
NVLX selects TD2 to conduct preclinical and clinical studies. i.e. the mice studies- where is it
NVLX and PMCB begin preclinical studies never started
NVLX begins studies for treatment of Ascites Fluid and failed
TD2 joins NVLX to begin studies showing that CiaB can slow the accumulation of Ascites Fluid. and TD2 bailed
NVLX submits application for ODD to EMA. so what
NVLX submits application for ODD to FDA. so what
NVLX secures world-wide license for Insulin producing cells for Diabetes. so what
NVLX forms Diabetes Consortium with Professor Ann Simpson and she is gone
NVLX announces opening of Austrianova's cGMP Live Cell Encapsulation Facility. in 3 world country
First live cell encapsulation at new facility just 14 days after it opens. that didn't work
FDA grants ODD to NVLX for Pancreatic Cancer with marketing exclusivity. so what
This is the end of 2014 and KW has done a ton including setting the base for everything PMCB is doing today. At this time clinical trials have not been scheduled yet.
NVLX changes name to PharmaCyte Biotech. to fool shareholders
PMCB initiates first preclinical study of encapsulation of cells for Diabetes.
PMCB finds in addition to everything else CiaB can do it can also consistently shrink tumors. wrong
PMCB begins talking clinical trial dates. that never will happen
Research shows that PMCB's Melligen Cell Line can reverse Diabetes. Melligen cells complete failure
PMCB completes formation of International Diabetes Consortium to cure Diabetes. again complete failure
Melligen Cells prove safe in first preclinical test in Vienna. again complete failure
PMCB appoints Dr. Manuel Hidalgo to Scientific Advisory Board off of his work with CiaB in the preclinical studies at TD2. and Von Hoff bailed leaving this has been
Interim Audit of cGMP facility is successful. by who
PMCB brings Imagining Endpoints on-board to assist in Radiological Imaging for Phase IIB trials
PMCB and TD2 begin to redesign trial design. TD2 has nothing to do with PMCB
PMCB obtains ODD from EMA and additional marketing exclusivity.
PMCB and TD2 meet to re-design of the trial design.
PMCB announces that trial still on target for late 2016.
PMCB and TD2 finalize trial design and is completely re-written.
cGMP finally granted by Thai Government with full go-ahead. Obviously PMCB has no control over how long it takes a country's government to approve a facility like this. but not by the FDA
PMCB receives patent protection of melligen cells to treat Diabetes. compete failure
Submission of an Investigational New Drug application (IND) to the U.S. FDA requesting authorization to administer its investigational therapy to humans in a proposed Phase 2b clinical trial. and rejected by the FDA
PharmaCyte Biotech Begins DNA Sequence and Stability Studies in Response to FDA Requests for its Clinical Trial Product and rejected by the FDA
PharmaCyte Biotech Begins Physical Testing of CypCaps in Response to FDA Recommendations for its Clinical Trial Product
PharmaCyte Biotech Successfully Completes 9-Month Stability Study so what
Completed a medical manual pivotal to the completion of its Investigational New Drug application and rejected by the FDA
Pharmacyte completes 6 month stability study
Pharmacyte completes second container closure integrity study
Pharmacyte successfully develops “change history” for its clinical trial product.
Pharmacyte completes medical manual IND filing
Pharmacyte successfully completes all release testing on clinical trial record
AMENDMENT NO. 3 TO THE BYLAWS
OF
PHARMACYTE BIOTECH, INC.
September 20, 2018
Pursuant to Article 8 of the Amended and Restated Bylaws (the “Bylaws”) of PharmaCyte Biotech, Inc., a corporation organized and existing under the laws of the State of Nevada (the “Corporation”), the Corporation hereby certifies that:
ONE: The Bylaws are hereby amended by this Amendment as follows:
Article 4, Section 2 is hereby deleted in its entirety and replaced with the following:
“Section 2. ANNUAL MEETINGS. The annual meeting of the Shareholders shall be held at such time and place as may be designated from time to time by the Board of Directors for the purpose of electing directors and for the transaction of such other business as may properly be brought before the meeting.”
Article 4, Section 8 is hereby deleted in its entirety and replaced with the following:
“Section 8. QUORUM. The holders of one-third (1/3) of the voting power of the Corporation’s stock entitled to vote, present in person, or represented by proxy, shall constitute a quorum at all meetings of the Shareholders for the transaction of business except as otherwise provided by law, by the Articles of Incorporation, or by these By-Laws. If, however, such quorum shall not be present or represented at any meeting of the Shareholders, the shareholders entitled to vote, present in person, or represented by proxy, shall have the power to adjourn the meeting from time to time, until the requisite amount of voting power shall be present. At such adjourned meeting at which the requisite amount of voting power shall be represented, any business may be transacted which might have been transacted at a meeting as originally notified.
If a quorum be initially present, the Shareholders may continue to transact business until adjournment, notwithstanding the withdrawal of enough Shareholders to leave less than a quorum, if any action taken is approved by a majority of the voting power required to initially constitute a quorum.”
TWO: Except as expressly amended by the terms of this Amendment, all the terms and provisions of the Bylaws shall remain in full force and effect, and shall not be deemed modified, altered, or otherwise affected by this Amendment.
THREE: This Amendment has been duly adopted in accordance with the provisions of Article 8 of the Bylaws by the Board of Directors of the Corporation.
IN WITNESS WHEREOF, the Corporation has caused this Amendment to be signed by its Chief Executive Officer as of the date first written above.
PHARMACYTE BIOTECH, INC.
By: /s/ Kenneth L. Waggoner
Kenneth L. Waggoner, Chief Executive Officer
list of all of PMCBs failures
KW officially takes over as President of NVLX
NVLX immediately acquires 14.5% equity interest in Austrianova. First vision
NVLX contracts with Austrianova to encapsulate cells for clinical trials.
NVLX selects TD2 to conduct preclinical and clinical studies. i.e. the mice studies-
NVLX and PMCB begin preclinical studies
NVLX begins studies for treatment of Ascites Fluid
TD2 joins NVLX to begin studies showing that CiaB can slow the accumulation of Ascites Fluid.
NVLX submits application for ODD to EMA.
NVLX submits application for ODD to FDA.
NVLX secures world-wide license for Insulin producing cells for Diabetes.
NVLX forms Diabetes Consortium with Professor Ann Simpson
NVLX announces opening of Austrianova's cGMP Live Cell Encapsulation Facility.
First live cell encapsulation at new facility just 14 days after it opens.
FDA grants ODD to NVLX for Pancreatic Cancer with marketing exclusivity.
This is the end of 2014 and KW has done a ton including setting the base for everything PMCB is doing today. At this time clinical trials have not been scheduled yet.
NVLX changes name to PharmaCyte Biotech.
PMCB initiates first preclinical study of encapsulation of cells for Diabetes.
PMCB finds in addition to everything else CiaB can do it can also consistently shrink tumors.
PMCB begins talking clinical trial dates.
Research shows that PMCB's Melligen Cell Line can reverse Diabetes.
PMCB completes formation of International Diabetes Consortium to cure Diabetes.
Melligen Cells prove safe in first preclinical test in Vienna.
PMCB appoints Dr. Manuel Hidalgo to Scientific Advisory Board off of his work with CiaB in the preclinical studies at TD2.
Interim Audit of cGMP facility is successful.
PMCB brings Imagining Endpoints on-board to assist in Radiological Imaging for Phase IIB trials
PMCB and TD2 begin to redesign trial design.
PMCB obtains ODD from EMA and additional marketing exclusivity.
PMCB and TD2 meet to re-design of the trial design.
PMCB announces that trial still on target for late 2016.
PMCB and TD2 finalize trial design and is completely re-written.
cGMP finally granted by Thai Government with full go-ahead. Obviously PMCB has no control over how long it takes a country's government to approve a facility like this.
PMCB receives patent protection of melligen cells to treat Diabetes.
Submission of an Investigational New Drug application (IND) to the U.S. FDA requesting authorization to administer its investigational therapy to humans in a proposed Phase 2b clinical trial.
PharmaCyte Biotech Begins DNA Sequence and Stability Studies in Response to FDA Requests for its Clinical Trial Product
PharmaCyte Biotech Begins Physical Testing of CypCaps in Response to FDA Recommendations for its Clinical Trial Product
PharmaCyte Biotech Successfully Completes 9-Month Stability Study
Completed a medical manual pivotal to the completion of its Investigational New Drug application
Pharmacyte completes 6 month stability study
Pharmacyte completes second container closure integrity study
Pharmacyte successfully develops “change history” for its clinical trial product.
Pharmacyte completes medical manual IND filing
Pharmacyte successfully completes all release testing on clinical trial record.
that leaves out kenny
kenny appoints fauci to PMCB board
FDA rejected PMCBs IND 3 days after it wa summited all in the 10q
FDA rejected PMCBs IND
yeah I see a lot of .01 stocks on the NASDAQ
Ciab doesn't work 123= reason for FDA rejecting PMCBs IND
Think its a failure 1,2,3= PMCB
Hidalgo no ethics or integrity......will say anything if you pay him
Hidalgo no ethics or integrity......will say anything if you pay him
here is proof kenny boy said it right in the filing
"Evaluation of Disclosure Controls and Procedures Our Chief Executive Officer, President and General Counsel, as our principal executive officer (“Chief Executive Officer”), and our Chief Financial Officer, as our principal financial officer (“Chief Financial Officer”), evaluated the effectiveness of our “disclosure controls and procedures,” "Based upon this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that, as of January 31, 2021, our disclosure controls and procedures were not effective due to the material weaknesses in internal control over financial reporting
FDA rejected PMCBs IND
I didn't DREAM it, it happened FDA rejected PMCBs IND
Hidalgo no ethics or integrity......will say anything if you pay him
and just think with all this excitement pmcb still going down
well I watch and learned PMCB will not be 2 cents these week......good lesson
And you like throwing the words around "2 previous trials" but have yet to prove it...FDA rejected PMCBs IND
one more day for PMCB to reach 2 cents
Crabtree and Hidalgo both has beens
Fell out of my chair while eating breakfast reading this previous successful clinicals LOL there are none......FDA rejected PMCBs IND
when was the last time you seen a penny stock on the NASDAQ PMCB .0125 what a joke
where is that 2 cent this week for PMCB
old news they are both has beens
Crabtree and Yuen have no reputations they are both hacks
what day this week will PMCB be 2 cents I want to learn
the last vote was September 2020 so keen failed again at that requirement
I see FAILURE in PMCB future, and no NASDAQ
Yuen could take over as pmcb CEO and the IND will still be rejected by the FDA
so kennys wonder treatment has no patent protection,,,,,,,,LOL what a joke this company is
I hear pmcb will be 2 cents next week.....I will be here